Skyepharma Plc has purchased rights to a respiratory technology platform from Pulmagen Therapeutics (Synergy) Ltd that could form the basis of a range of new products for chronic obstructive pulmonary disease (COPD). ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
